Jupiter Neurosciences Inc (JUNS)

$JUNS Don’t be shy! I know you are ending red 🤣🤣

$JUNS AGRZ 👀

$JUNS There is no single day that I don’t curse this shit!! What’s wrong with this company?!!!

$JUNS I bet this piece of shit will drop more today !! 🤬

$JUNS how did I end up here?? ✅💚😂

$JUNS wtf. Short more?

$JUNS $UFG I expect to see a return of at least 20% or 30%, or even more, on each soon. Juns needs to regain Nasdaq's performance and will likely do so, just like a year ago. They might surprise us in their next financial report. UFG is doing well; perhaps they could have a surprise announcement soon, but purely speculatively, I think they could return to 1.25 soon.

$JUNS I got robbed on this turd 💩

$JUNS I know several people that are victims of this scam described in this video , this stock $JUNS was one of the multiple stocks that was used for this scam. I fell for it too https://youtu.be/JHdJEYJ6ucY?si=G2Z9LwlzjZRNEH5K

The B2i Digital team is pleased to announce that Jupiter Neurosciences, Inc. (Nasdaq: $JUNS ), a B2i Digital Featured Company, is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Tuesday, March 11, 2026, at 1:30 PM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum For the full B2i Digital profile of Jupiter Neurosciences, please visit: https://b2idigital.com/jupiter-neurosciences-1 Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia, a consumer product built on its patented JOTROL technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation. Presenting on behalf of Jupiter Neurosciences will be Christer Rosén, Founder, Chairman and Chief Executive Officer. Mr. Rosén brings a track record of building companies across multiple industries. He previously served as Chairman and CEO of EffRx Pharmaceuticals for 17 years, where he guided the company through FDA and EU approvals of Binosto, a treatment for osteoporosis, providing him with extensive experience across pharmaceutical development, regulatory pathways and global distribution. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Jupiter Neurosciences, visit: https://jupiterneurosciences.com/investors/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.